Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines
Phase of Trial: Phase III
Latest Information Update: 20 Dec 2018
At a glance
- Drugs Isatuximab (Primary) ; Carfilzomib; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms IKEMA
- Sponsors Sanofi
- 12 Dec 2018 Planned End Date changed from 24 Aug 2023 to 1 Oct 2023.
- 12 Dec 2018 Planned primary completion date changed from 24 Aug 2023 to 1 Oct 2023.
- 10 Oct 2018 Planned End Date changed from 26 Jun 2023 to 24 Aug 2023.